The Generic Cliff Doesn’t “Hit” — It’s Engineered Around.
If you’ve ever wondered why some pharma companies seem to “beat” expiring patents while others get crushed by the generic wave, the answer isn’t just luck or better legal strategy. It’s engine…

Patent thickets are the new moat—and biologics are the new battleground.
If you’ve ever wondered why some blockbuster drugs seem to face delays in competition for years (even when the “main” patent should be expiring), the answer is rarely a single p…

AI Prior Art Search: How to Invalidate Key Drug Patents Before You Pay
Most people think patent risk is something you deal with after you’ve already spent the money—after the deal is signed, after the formulation is locked, after the regulatory path is…

Most teams treat formulation patents like a black box. That’s why they miss the design-around window.
In pharma, the “real” competitive advantage often isn’t the active ingredient—it’s the formulation. Yet formulation patents are frequently approached …

Russia’s latest VED/SSM list update isn’t just another regulatory footnote—it’s a real-time stress test for how quickly generics can (and can’t) enter the market.
If you’re a brand owner, it’s a reminder that “patent life” is only half the story. The o…

Pharma pipelines don’t fail because of science. They fail because of timing.
One missed patent, one overlooked regulatory exclusivity, one “minor” formulation change that triggers a new claim—suddenly your launch window evaporates and your investors …

Beyond the ANDA: How the 505(b)(2) Pathway Can Turn “Copy” Into Differentiation—and Defense
Most pharma conversations about generics start and end with the ANDA. But if you’re building a product strategy—not just a filing calendar—the real leverage oft…

Pharma IP teams are used to thinking in timelines: filing dates, priority windows, prosecution milestones, and—eventually—patent expiry. But in Russia, the clock can move in ways that don’t always show up in your standard global playbook.
A recent Drug…

Litigation-Aware Prosecution: Turn Your Drug Patent Portfolio Into a Competitive Assertion Asset
In pharma, “getting a patent” is often treated like the finish line. But for many companies, it’s actually the starting gun—because the real value of a dru…

Hospitals are sitting on a quiet, expensive blind spot: patent expiration intelligence.
Not the kind you hear about in boardrooms—where “biosimilars” and “generic launches” are treated like distant market events. I mean the operational reality: when a …